Lilly looks to 'protect its interests' by moving to join FDA lawsuit over compounded tirzepatide
2nd January 2025 Uncategorised 0After plugging $23 billion into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking to wade into a lawsuit that could allow compounding pharmacies to continue churning out the popular diabetes and obesity drugs.
read more